A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects

Table 2 BED comparison between standard and explored RT schedule

RT schedule	BED tumor control α/β₄		BED acute effects α/β₁₀		BED fibrosis α/β_1.7		BED vascular damage α/β_2.5
W.B. = whole breast B.S. = tumor bed side	W.B.	B.S.	W.B.	B.S.	W.B.	B.S.	W.B.	B.S.
60 Gy/30 F/6 W (50 Gy + 10 Gy seq.boost)	75	90	60	72	109	131	90	108
50 Gy/25 F/5 W (no boost)	75	75	60	60	109	109	90	90
42 Gy/13 F/3W + 1 day (39 Gy + 3 Gy cc.boost)	68	77	51	56	108	123	86	97
52 Gy/20/F/5 W (46 Gy + 6 Gy cc.boost)	72	87	57	66	108	135	88	108
UK START TRIAL A 41.6 Gy/13 F/5 W	75	75	55	55	120	120	95	95
UK START TRIAL A 39 Gy/13 F/5W	68	68	51	51	108	108	86	86

boost = concomitant boost; seq.boost = sequential boost; F = fractions; W = weeks

ISSN: 1748-717X